The New York Times: LOS ANGELES — The first year of skirmishes in state legislatures over bills that would govern the use of cheaper versions of expensive biotechnology drugs is nearly over. Health insurers and generic drug companies have prevailed in most states over brand-name pharmaceutical companies.
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Nowi360Gov is an intelligent network of websites and e-newsletters that provides government business, policy and technology leaders with a single destination for the most important news and analysis regarding their agency strategies and initiatives.
Telephone: 202.760.2280
Toll Free: 855.i360.Gov
Fax: 202.697.5045
The most significant government policy, business, and technology news and analysis delivered to your inbox.
Subscribe Now